Roche

Biotech

Sangamo Therapeutics Inks $1.95B Deal With Genentech to Target Alzheimer’s, SGMO Stock Pops 29%

In a significant advancement for the field of genomic medicine, Sangamo Therapeutics has entered a landmark license agreement with Genentech,…

Read More »
Biotech

Investors Shift Focus From Vaccine Stocks to COVID Pill Stocks

Nearly two years since the COVID-19 pandemic began and almost one year since the various COVID-19 vaccines started to roll…

Read More »
Back to top button